CR20120277A - Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa - Google Patents

Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa

Info

Publication number
CR20120277A
CR20120277A CR20120277A CR20120277A CR20120277A CR 20120277 A CR20120277 A CR 20120277A CR 20120277 A CR20120277 A CR 20120277A CR 20120277 A CR20120277 A CR 20120277A CR 20120277 A CR20120277 A CR 20120277A
Authority
CR
Costa Rica
Prior art keywords
hemitartrate
glucosilceramide
amorphy
sintasa
genz
Prior art date
Application number
CR20120277A
Other languages
English (en)
Inventor
Harlin Liu
Chris Willis
Renu Bhardwaj
Diane P Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Jianmei Kochling
Gerard Palace
Judith Peterschmitt
Craig Siegel
Seng Cheng
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120277(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CR20120277A publication Critical patent/CR20120277A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Se desvela la sal de hemitartrato de un compuesto representado por la fórmula estructural, que puede utilizarse en aplicaciones farmacéuticas. Las formas cristalinas únicas particulares de Hemitartrato de formúla (I) se caracterizan por una variedad de propiedades y mediciones físicas.
CR20120277A 2009-11-27 2012-05-24 Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa CR20120277A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27

Publications (1)

Publication Number Publication Date
CR20120277A true CR20120277A (es) 2012-09-05

Family

ID=43431870

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120277A CR20120277A (es) 2009-11-27 2012-05-24 Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa

Country Status (41)

Country Link
US (6) US11458119B2 (es)
EP (5) EP3896069A1 (es)
JP (6) JP2013512252A (es)
KR (5) KR20120115972A (es)
CN (5) CN102712629B (es)
AR (3) AR079152A1 (es)
AU (3) AU2010324810B2 (es)
BR (1) BR112012012947B8 (es)
CA (3) CA2781676C (es)
CL (2) CL2012001348A1 (es)
CR (1) CR20120277A (es)
CY (3) CY1115880T1 (es)
DK (3) DK3133070T3 (es)
DO (2) DOP2012000141A (es)
EA (3) EA201890254A3 (es)
EC (2) ECSP12011926A (es)
ES (4) ES2875382T3 (es)
GT (1) GT201200161A (es)
HK (2) HK1203485A1 (es)
HR (3) HRP20140780T4 (es)
HU (2) HUE029371T2 (es)
IL (4) IL310635A (es)
LT (2) LT3133070T (es)
MA (1) MA33838B1 (es)
ME (1) ME02477B (es)
MX (1) MX358345B (es)
MY (2) MY160542A (es)
NI (1) NI201200096A (es)
NZ (3) NZ625712A (es)
PE (2) PE20171255A1 (es)
PH (1) PH12015502514A1 (es)
PL (4) PL3599237T3 (es)
PT (4) PT2504332E (es)
RS (3) RS59543B1 (es)
SG (2) SG10201407881WA (es)
SI (3) SI2796457T1 (es)
SM (1) SMT201600273B (es)
TN (1) TN2012000237A1 (es)
TW (3) TWI586663B (es)
UA (1) UA113491C2 (es)
WO (1) WO2011066352A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
AU2010324810B2 (en) 2009-11-27 2016-05-12 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
JP6175431B2 (ja) * 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法
LT2753346T (lt) 2011-09-07 2020-08-10 Mount Sinai School Of Medicine Ceramidazė ir ląstelių diferenciacija
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
ES2897825T3 (es) 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
EP2968479B1 (en) 2013-03-14 2019-07-17 Icahn School of Medicine at Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
CN110372636B (zh) * 2013-09-20 2023-03-28 生物马林药物股份有限公司 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
WO2016001885A2 (en) * 2014-07-03 2016-01-07 Dr. Reddy’S Laboratories Limited Amorphous form of eliglustat hemitartarate
WO2016166170A1 (en) 2015-04-14 2016-10-20 Sandoz Ag Crystalline eliglustat hydrochloride
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
MX2018006250A (es) 2015-11-18 2018-09-05 Genzyme Corp Biomarcador de enfermedad poliquistica renal y usos del mismo.
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) * 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
ZA201803719B (en) 2017-06-05 2019-04-24 Cipla Ltd Stable solid dispersions of eliglustat hemitartrate
MX2019015177A (es) * 2017-06-16 2020-02-07 Beta Pharma Inc Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas.
US20200222310A1 (en) * 2017-08-08 2020-07-16 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
WO2019030645A1 (en) * 2017-08-08 2019-02-14 Kashiv Pharma Llc Pharmaceutical composition comprising eliglustat
EP3723809A1 (en) 2017-12-15 2020-10-21 Genzyme Corporation Methods for treating gaucher disease
WO2019123476A1 (en) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
WO2019211778A2 (en) * 2018-05-02 2019-11-07 Kashiv Biosciences, Llc Pro-drugs of eliglustat
US20210113703A1 (en) * 2018-05-27 2021-04-22 Bioasis Technologies Inc. Treatment of gaucher disease
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
HUT73527A (en) 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
DE69518627T2 (de) 1994-02-02 2001-01-11 Liposome Co Inc Pharmazeutisch wirksame verbindungen und liposome und verfahren zu deren herstellung
JP3850437B2 (ja) 1994-06-10 2006-11-29 生化学工業株式会社 ２−アシルアミノプロパノール化合物及び医薬組成物
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
AU756008B2 (en) 1998-07-27 2003-01-02 Johns Hopkins University, The Methods for treating conditions modulated by lactosylceramide
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
CA2378600A1 (en) * 1999-07-09 2001-01-18 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
EP1384719A1 (en) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
YU79402A (sh) 2000-04-24 2006-03-03 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartrat
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
BR0206400A (pt) 2001-01-10 2005-01-18 Univ Michigan Compostos de amino ceramidas e seus usos em métodos terapêuticos
CA2435037A1 (en) 2001-01-18 2002-07-25 Silke Schumacher Bifunctional fusion proteins with glucocerebrosidase activity
PT2266968E (pt) 2001-07-16 2013-02-25 Genzyme Corp Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
AU2002328092A1 (en) 2001-08-08 2003-02-24 Takeda Chemical Industries, Ltd. Bicyclic compound, production and use as hiv inhibitors
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
AU2003251829B2 (en) 2002-07-09 2009-12-10 Radical Therapeutix Method to inhibit ischemia and reperfusion injury
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
AR047459A1 (es) * 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
EP1799865B1 (en) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
EP2708531A1 (en) 2004-10-13 2014-03-19 Pharmacia & Upjohn Company LLC Crystalline Forms Of 3-[5-Chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
WO2007038676A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
CN101277959A (zh) * 2005-10-03 2008-10-01 马林克罗特公司 制备唑吡坦半酒石酸盐和酒石酸盐多晶型的方法
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
ES2546181T3 (es) * 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
CA2682441A1 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
EP2150254A4 (en) * 2007-04-26 2010-11-10 Amicus Therapeutics Inc DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES
WO2008150486A2 (en) * 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
US20090307179A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
DK2504334T3 (en) 2009-11-27 2014-12-08 Bayer Ip Gmbh PROCEDURE FOR PURIFICATION OF METHYL- {4,6-DIAMINO-2- [1- (2-FLUOROBENZYL) -1H-PYRAZOLO [3,4-B] PYRIDIN-3-YL] PYRIMIDIN-5-YL} METHYL CARBAMATE
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
AU2010324810B2 (en) 2009-11-27 2016-05-12 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
MX2013014887A (es) 2011-06-21 2014-02-17 Novartis Ag Polimorfos de 1- ({4-metil-5- [2- (2 ,2 ,2-trifluoro-1,1-dimetil-e til) piridin-4-il] - tiazol-2-il}-amida de 2-amida del acido (s) -pirrolidin-1,2-dicarboxilico.
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
NZ600155A (en) 2014-10-31
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
SG10201800136QA (en) 2018-02-27
LT3133070T (lt) 2019-11-11
DK2504332T3 (da) 2014-08-25
DK2796457T3 (en) 2016-08-29
DOP2012000141A (es) 2012-09-30
ES2875382T3 (es) 2021-11-10
EA201890254A3 (ru) 2019-02-28
EP3133070A1 (en) 2017-02-22
IL219892A0 (en) 2012-07-31
JP2013512252A (ja) 2013-04-11
JP2023116764A (ja) 2023-08-22
CN102712629A (zh) 2012-10-03
HRP20140780T4 (hr) 2021-08-06
SI3133070T1 (sl) 2019-11-29
JP2016138124A (ja) 2016-08-04
JP7150528B2 (ja) 2022-10-11
CL2016002589A1 (es) 2017-05-19
KR20220162824A (ko) 2022-12-08
EP2504332B1 (en) 2014-06-04
PE20171255A1 (es) 2017-08-28
AU2010324810A1 (en) 2012-06-07
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
US20230172903A1 (en) 2023-06-08
EP3133070B1 (en) 2019-08-14
CN105777707B (zh) 2020-10-13
ES2754398T3 (es) 2020-04-17
AU2017265180B2 (en) 2019-08-01
SI2504332T1 (sl) 2014-09-30
EP2796457B1 (en) 2016-05-18
EP3599237A1 (en) 2020-01-29
CA3075788C (en) 2021-12-21
CN112521367A (zh) 2021-03-19
RS59543B1 (sr) 2019-12-31
US20130137743A1 (en) 2013-05-30
TW201737910A (zh) 2017-11-01
CN112521366A (zh) 2021-03-19
ECSP18063798A (es) 2020-02-28
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
PL3133070T3 (pl) 2020-01-31
EP2504332B2 (en) 2021-03-17
CY1117996T1 (el) 2017-05-17
EP3599237B1 (en) 2021-03-24
CA2781676A1 (en) 2011-06-03
TWI656873B (zh) 2019-04-21
UA113491C2 (xx) 2017-02-10
DK3133070T3 (da) 2019-11-11
CN105753846B (zh) 2019-11-15
PL2504332T5 (pl) 2021-08-23
CA3075788A1 (en) 2011-06-03
ME02477B (me) 2017-02-20
RS53503B1 (en) 2015-02-27
SG10201407881WA (en) 2015-01-29
DK2504332T4 (da) 2021-06-07
HK1172031A1 (en) 2013-04-12
MY192644A (en) 2022-08-29
TN2012000237A1 (en) 2013-12-12
HRP20161038T1 (hr) 2016-10-21
CL2012001348A1 (es) 2012-08-24
US20160166542A1 (en) 2016-06-16
BR112012012947B8 (pt) 2021-05-25
ES2586947T3 (es) 2016-10-19
AR121612A2 (es) 2022-06-22
SI2504332T2 (sl) 2021-08-31
CY1122698T1 (el) 2021-03-12
HRP20140780T1 (en) 2014-11-07
EA201890254A2 (ru) 2018-10-31
KR20150125734A (ko) 2015-11-09
US20210369672A1 (en) 2021-12-02
HUE045784T2 (hu) 2020-01-28
US10888547B2 (en) 2021-01-12
PT3133070T (pt) 2019-11-11
KR20200013105A (ko) 2020-02-05
AU2017265180A1 (en) 2017-12-14
JP6370264B2 (ja) 2018-08-08
CA3140959A1 (en) 2011-06-03
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
EP3896069A1 (en) 2021-10-20
LT2796457T (lt) 2016-09-12
CN102712629B (zh) 2016-10-12
BR112012012947A2 (pt) 2017-03-01
TW201639562A (zh) 2016-11-16
JP6452635B2 (ja) 2019-01-16
PH12015502514A1 (en) 2016-08-15
RS54978B1 (sr) 2016-11-30
IL283935A (en) 2021-07-29
WO2011066352A1 (en) 2011-06-03
AR079152A1 (es) 2011-12-28
IL310635A (en) 2024-04-01
DOP2016000250A (es) 2017-02-15
ES2493940T5 (es) 2021-11-23
PT3599237T (pt) 2021-04-28
HK1203485A1 (zh) 2015-10-30
JP2020189873A (ja) 2020-11-26
TW201130822A (en) 2011-09-16
MX2012006083A (es) 2012-06-19
CN112521367B (zh) 2024-01-02
MY160542A (en) 2017-03-15
SMT201600273B (it) 2016-08-31
HUE029371T2 (en) 2017-02-28
PL2504332T3 (pl) 2014-10-31
EP2796457A1 (en) 2014-10-29
ECSP12011926A (es) 2012-07-31
PL2796457T3 (pl) 2017-04-28
MA33838B1 (fr) 2012-12-03
PT2504332E (pt) 2014-09-02
ES2493940T3 (es) 2014-09-12
SI2796457T1 (sl) 2016-10-28
BR112012012947B1 (pt) 2021-04-06
KR20120115972A (ko) 2012-10-19
IL260299A (en) 2018-08-30
AU2016202591A1 (en) 2016-05-19
TWI586663B (zh) 2017-06-11
TWI606827B (zh) 2017-12-01
US20210393590A1 (en) 2021-12-23
CY1115880T1 (el) 2017-01-25
PL3599237T3 (pl) 2021-09-27
PT2796457T (pt) 2016-07-14
GT201200161A (es) 2014-01-27
AU2016202591B2 (en) 2017-11-30
EP2504332A1 (en) 2012-10-03
WO2011066352A8 (en) 2011-08-11
EA029990B1 (ru) 2018-06-29
EA023923B1 (ru) 2016-07-29
HRP20191647T1 (hr) 2019-12-13
EA201270646A1 (ru) 2013-01-30
EA201592195A1 (ru) 2016-04-29
US20160120842A1 (en) 2016-05-05
NI201200096A (es) 2012-10-30
NZ715108A (en) 2017-06-30
KR20180049255A (ko) 2018-05-10
RS53503B2 (sr) 2021-07-30
JP2019001809A (ja) 2019-01-10
CA2781676C (en) 2020-05-05
US11458119B2 (en) 2022-10-04
JP2015212291A (ja) 2015-11-26

Similar Documents

Publication Publication Date Title
CR20120277A (es) Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa
CY1123777T1 (el) Συνθετικο ενδιαμεσο χρησιμο στην παρασκευη αναστολεων c-met τριαζολοπυριδινης
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
NI201200192A (es) Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica.
CR20140084A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
ECSP14004812A (es) Triazolopiridinas sustituidas
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
RS54730B1 (sr) Inhibitori beta sekretaze
EA201101148A1 (ru) Новые гербициды
CR20110403A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia
EA201101146A1 (ru) Новые гербициды
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
CR20130594A (es) Monohidrato de derivados de aza-adamantano
EA201101097A1 (ru) Новые микробиоциды
UY35036A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
ME00929B (me) NOVI POSTUPAK ZA DOBlJANJE KRISTALNOG OBLIKA V AGOMELATIN A
EA201200150A1 (ru) Новые гербициды
CY1116535T1 (el) Μεθοδος συνθεσης παραγωγων της 7,8-διμεθοξυ-1,3-διυδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη στην συνθεση της ιβαμπραδινης
TH106828B (th) สารยับยั้งไพร์โรโลไพราซีนคิเนส
CU20100127A7 (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CR20120434A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6